The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients.
Adel Jebar
No relevant relationships to disclose
Emma West
No relevant relationships to disclose
Karen Scott
No relevant relationships to disclose
Simon Thomson
No relevant relationships to disclose
Robert Corns
No relevant relationships to disclose
Matthew C. Coffey
Employment or Leadership Position - Oncolytics Biotech
Ailsa Rose
No relevant relationships to disclose
Gerard Nuovo
Consultant or Advisory Role - Oncolytics Biotech
Matthew Ryan
No relevant relationships to disclose
Fiona Errington-Mais
No relevant relationships to disclose
Christy Ralph
No relevant relationships to disclose
Christopher Twelves
No relevant relationships to disclose
Stephen Griffin
No relevant relationships to disclose
Kevin J. Harrington
Research Funding - Oncolytics Biotech
Hardev S. Pandha
No relevant relationships to disclose
Olly Donnely
No relevant relationships to disclose
Peter John Selby
No relevant relationships to disclose
Richard Vile
No relevant relationships to disclose
Susan Short
No relevant relationships to disclose
Alan Melcher
Research Funding - Oncolytics Biotech